immune gene expression patterns associated with molecular subtypes of MIBC.
METHODS: We utilized the publicly available global transcriptomic sequencing (RNA-Seq) data from 412 MIBC cases, with the corresponding clinical information downloaded from The Cancer Genome Atlas (TCGA) data Portal. Cases were divided into discovery (n¼122) and validation (n¼245) cohorts for downstream analysis and were divided into four clusters based on their genomic profiles. To investigate the presence of subtype associated immune signatures we assembled a defined set of 828 immune related genes, consisting of genes involved primarily in Type I and II interferon pathways in addition to other immune response and immune cell phenotype genes. All downstream data analysis was performed in R Bioconductor statistical environment. A one-way ANOVA was utilized to determine significantly differentially expressed genes with a Benjamini and Hochberg correction for false-discovery rate (FDR) correction of q<0.05.
RESULTS: In the 122 case discovery cohort, we identified a total of 452 genes differentially expressed among the four clusters with an FDR q<0.05. The performance of these differentially expressed genes to accurately distinguish the four TCGA clusters was evaluated by unsupervised clustering of both genes and samples. The 64 top 20% of ranked genes were able to distinguish the four clusters in an unsupervised analysis of both the discovery and validation cohorts. The most enriched biological processes in the 452 gene list were response to IFN-g, antigen processing and presentation, cytokine mediated signalling, cell proliferation, NK cell and macrophage activation and B cell mediated immunity The top five overrepresented pathways included, JAK/STAT signalling pathway, Toll receptor signalling pathway, interleukin signalling pathway, and T cell activation. Kaplan Meier survival analysis revealed that in combination, higher expression of three genes, SA100A7, S100A8 and SERPINB2 significantly associated with decreased survival only between clusters I and III in both discovery and validation cohorts.
CONCLUSIONS: Recent evolving findings from completed immunotherapy based clinical trials have emphasized the value of preexisting tumour immune state that potentially determines response to treatment and survival. Our analyses reveal a grouping of immune gene expression patterns using both supervised and unsupervised clustering approaches. Given that specific genetic alterations associate with these molecular subtypes it seems that anti-tumour immune responses could be partly driven by oncogenic drivers. The findings provide further insights into the association between genomic subtypes and immune activation in MIBC and may open novel opportunities for their exploitation towards precise treatment with immunotherapy.
Source of Funding: none
MP88-06 NUCLEAR FACTOR (NF)-kB SIGNALS PROMOTE UROTHELIAL TUMORIGENESIS THROUGH THE ANDROGEN RECEPTOR (AR) PATHWAY Hiroki Ide*, Tokyo, Japan; Satoshi Inoue, Taichi Mizushima, Rochester, NY; Mototsugu Oya, Tokyo, Japan; George Netto, Birmingham, AL; Hiroshi Miyamoto, Rochester, NY INTRODUCTION AND OBJECTIVES: Emerging preclinical evidence has indicated the involvement of AR signaling in urothelial tumorigenesis. Meanwhile, cross-talk between AR and NF-kB, a protein complex of transcriptional factor and its phosphorylation is required for optimal induction of target genes, has been demonstrated in prostate cancer cells. We therefore investigated the role of NF-kB in neoplastic transformation of urothelial cells in relation to AR signaling.
METHODS: We immunohistochemically stained for NF-kB and phospho-NF-kB (p-NF-kB) in 149 bladder tumor and paired nonneoplastic bladder tissue specimens. Then, in immortalized human normal urothelial SVHUC sublines stably expressing AR with exposure to a chemical carcinogen 3-methylcholanthrene (MCA), we assessed the effects of NF-kB activator (betulinic acid; BA) and inhibitor (parthenolide; PAR) on the expression of AR, NF-kB p65 subunit, oncogenes, and tumor suppressors (via RT-PCR or western blot) as well as neoplastic transformation (via cell viability assay and plate/soft agar colony formation assays). Finally, N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN) was given to male C57BL/6 mice to induce bladder tumors.
RESULTS: NF-?B and p-NF-?B were positive in 100% [9% weak (1+), 40% moderate (2+), 51% strong (3+)] and 69% (44% 1+, 24% 2+, 1% 3+) of tumors, which was significantly elevated compared with non-neoplastic urothelial tissues [100% (25% 1+, 40% 2+, 35% 3+), P¼0.016 (0/1+/2+ vs. 3+); and 46% (36% 1+, 10% 2+), p<0.001 (0 vs. 1+/2+/3+)]. Significantly higher rates of p-NF-kB positivity were also seen in high-grade (76%, P¼0.015) or muscle-invasive (78%, P¼0.033) tumors than in low-grade (56%) or non-muscle-invasive (62%) tumors. In SVHUC-AR cells, BA induced and PAR reduced the expression of p65 and AR. Notably, BA accelerated and PAR prevented neoplastic transformation of MCA-SVHUC-AR cells, but not that of MCA-SVHUC cells. Additionally, in MCA-SVHUC-AR cells, BA upregulated the expression of c-myc and down-regulated that of p53, p21, and UGT1A, while PAR showed the opposite results. Moreover, bladder tumors were identified in 56% (mock), 89% (BA), and 22% (PAR) of BBN-treated mice sacrificed at 21 weeks of age.
CONCLUSIONS: Compared with non-neoplastic urothelium, NF-kB appeared to be activated in bladder cancer. In addition, NF-kB modulators were found to involve the regulation of tumorigenesis in ARactivated urothelial cells. Accordingly, NF-kB inhibition, together with AR inactivation, has the potential of being an effective chemopreventive approach for urothelial carcinoma.
Source of Funding: None

MP88-07 ANDROGEN RECEPTOR ACTIVITY MODULATES RADIOSENSITIVITY IN BLADDER CANCER CELLS
Hiroki Ide*, Tokyo, Japan; Satoshi Inoue, Taichi Mizushima, Rochester, NY; Mototsugu Oya, Tokyo, Japan; Hiroshi Miyamoto, Rochester, NY INTRODUCTION AND OBJECTIVES: Although radiation therapy often with chemotherapy has been shown to offer survival rates comparable to radical cystectomy in select patients with bladder cancer, the development of radiosensitization may significantly enhance its application. Meanwhile, emerging preclinical evidence has indicated the involvement of androgen receptor (AR) signaling in urothelial cancer progression. In prostate cancer, AR has also been linked to radioresistance involving DNA repair pathways. We therefore assessed whether AR signals contribute to the sensitivity to radiotherapy in bladder cancer cells.
METHODS: We compared the inhibitory effects of irradiation (2 Gy) on bladder cancer cell viability or colony formation between ARpositive [e.g. UMUC3 expressing control-short hairpin RNA (shRNA), 5637 or 647V stably expressing wild-type AR] versus AR-negative lines (e.g. UMUC3 stably expressing AR-shRNA, 5637 or 647V expressing vector only) or between AR-positive lines with versus without treatment with dihydrotestosterone (DHT) or an anti-androgen hydroxyflutamide (HF). We also compared DNA double strand breaks (DSB) via g-H2AX foci formation in these cells after irradiation.
RESULTS: Ionizing radiation reduced the numbers of viable cells or colonies of AR-negative lines more significantly than those of AR-positive lines. Similarly, in AR-positive cells cultured in androgendepleted conditions, DHT treatment lowered the effects of irradiation. In AR-positive cells cultured in the presence of androgens, HF treatment then enhanced the effects of irradiation. Furthermore, the percentage of cells containing >10 g-H2AX foci in AR-negative lines was significantly higher than that in AR-positive lines after irradiation (4, 8, 12, and 24h) . DSB repair was also delayed by HF treatment in AR-positive cells after irradiation (4, 8, 12, and 24h) .
CONCLUSIONS: These findings suggest that AR activity correlates with the sensitivity to radiotherapy in bladder cancer cells. Accordingly, anti-androgenic drugs may function as sensitizers of irradiation, especially in patients with AR-positive urothelial cancer.
